Ischemic versus nonischemic dilated cardiomyopathy: The implications of heart failure etiology on left ventricular assist device outcomes

ASAIO Journal

Volumn 59, Issue 2, 2013, Pages 130-135

  Tsiouris, Athanasios ^a   Borgi, Jamil ^a   Karam, Joseph ^a   Nemeh, Hassan W ^a   Paone, Gaetano ^a   Brewer, Robert J ^a   Morgan, Jeffrey A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

cardiomyopathy; etiology of heart failure; left ventricular assist device; outcomes; reverse remodeling

Indexed keywords

CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; HEART FAILURE; LEFT VENTRICULAR ASSIST DEVICE (LVAD); MULTIVARIATE LOGISTIC REGRESSIONS; OUTCOMES; PERIPHERAL VASCULAR DISEASE; REVERSE REMODELING;

CARDIOVASCULAR SURGERY; DIAGNOSIS; LEFT VENTRICULAR ASSIST DEVICES; REGRESSION ANALYSIS;

CARDIOLOGY;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPARATIVE STUDY; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; INCIDENCE; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; RETROSPECTIVE STUDY; SURVIVAL; ADOLESCENT; CONGESTIVE CARDIOMYOPATHY; ECHOCARDIOGRAPHY; HEART ASSIST DEVICE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; LENGTH OF STAY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84874914387     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0b013e31828579af     Document Type: Article

References (22)

1. CIBIS Investigators and Committees: A randomized trial of betablockade in heart failure. The Cardiac Insuffciency Bisoprolol Study (CIBIS). Circulation 90(4):1765-1773, 1994.
2. Garg R, Yusuf S: Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450-1456, 1995.
3. MERIT-HF study group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-2007.
4. Poole-Wilson PA, Swedberg K, Cleland JG, et al; Carvedilol Or Metoprolol European Trial Investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362: 7-13, 2003.
5. Nony P, Boissel J P, Girard P, Leizorovicz A, Lievre M, Chiffet R: Relative effcacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure. Eur Heart J 13: 1101-1108, 1992.
6. Stevenson LW, Tillisch JH, Hamilton M, et al: Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 66: 1348-1354, 1990.
7. Likoff MJ, Chandler SL, Kay HR: Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 59: 634-638, 1987.
8. Ng AC, Sindone AP, Wong HS, Freedman SB: Differences in management and outcome of ischemic and non-ischemic cardio-myopathy. Int J Cardiol 129: 198-204, 2008.
9. Follath F, Cleland JG, Klein W, Murphy R: Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 32: 1167-1172, 1998.
10. Deng MC, Brisse B, Erren M, Khurana C, Breithardt G, Scheld HH: Ischemic versus idiopathic cardiomyopathy: Differing neurohu-moral profles despite comparable peak oxygen uptake. Int J Cardiol 61: 261-268, 1997.
11. Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ: Differential gene expression and genomic patient stratifca-tion following left ventricular assist device support. J Am Coll Cardiol 41: 1096-1106, 2003.
12. Heerdt PM, Schlame M, Jehle R, Barbone A, Burkhoff D, Blanck TJ: Disease-specifc remodeling of cardiac mitochondria after a left ventricular assist device. Ann Thorac Surg 73: 1216-1221, 2002.
13. Bruggink AH, van Oosterhout MF, de Jonge N, et al: Type IV collagen degradation in the myocardial basement membrane after unloading of the failing heart by a left ventricular assist device. Lab Invest 87: 1125-1137, 2007.
14. Mano A, Nakatani T, Oda N, et al: Which factors predict the recovery of natural heart function after insertion of a left ventricular assist system? J Heart Lung Transplant 27: 869-874, 2008.
15. Heerdt PM, Holmes JW, Cai B, et al: Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102: 2713-2719, 2000.
16. Bruggink AH, van Oosterhout MF, de Jonge N, et al: Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 25: 1091-1098, 2006.
17. Elliott P, Andersson B, Arbustini E, et al: Classifcation of the car-diomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29: 270-276, 2008.
18. Bart BA, Shaw LK, McCants CB Jr., et al: Clinical determinants of mortality in patients with angiographically diagnosed isch-emic or nonischemic cardiomyopathy. J Am Coll Cardiol 30: 1002-1008, 1997.
19. Butler CR, Jugdutt BI: The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated car-diomyopathy: Implications for heart failure in the elderly. Heart Fail Rev 17: 615-633, 2012.
20. de Weger RA, Schipper ME, Siera-de Koning E, et al: Proteomic profling of the human failing heart after left ventricular assist device support. J Heart Lung Transplant 30: 497-506, 2011.
21. de Jonge N, Kirkels H, Lahpor JR, et al: Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting? J Am Coll Cardiol 37: 1794-1799, 2001.
22. de Jonge N, van Wichen DF, Schipper ME, et al: Left ventricular assist device in end-stage heart failure: Persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myoflaments. J Am Coll Cardiol 39: 963-969, 2002.